Actively Recruiting
Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma
Led by Washington University School of Medicine · Updated on 2026-04-30
25
Participants Needed
1
Research Sites
836 weeks
Total Duration
On this page
Sponsors
W
Washington University School of Medicine
Lead Sponsor
P
Paula C. & Rodger O. Riney Blood Cancer Research
Collaborating Sponsor
AI-Summary
What this Trial Is About
Despite recent therapeutic advances, multiple myeloma (MM) remains an incurable disease. Although survival has improved, there are nevertheless diminishing durations of response to each subsequent line of therapy. This highlights the need for further therapeutic innovation. BCMA-targeting CAR-T cells show impressive response rates; however, their median duration of response is disappointing. The investigators propose that CS1(SLAMF7)-targeting CAR-T cells will fill a gap in the MM armamentarium. CS1 is an attractive target in MM because it is expressed in most patients. Elotuzumab (Empliciti®), an approved anti-CS1 antibody, has proven the clinical efficacy of this target. CAR-T cells are an ideal modality to target CS1, given that two approved treatments, ide-cel (idecabtagene vicleucel, AbecmaTM) and cilta-cel (ciltacabtagene autoleucel, Carvykti™), have proven the potential for cellular immunotherapy in MM. The investigators are testing the safety and preliminary anti-myeloma efficacy of WS-CART-CS1, a CAR-T cell therapy targeting CS1.
CONDITIONS
Official Title
Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Relapsed or refractory multiple myeloma after 3 or more prior lines of therapy, including proteasome inhibitors, anti-CD38 therapy, and anti-BCMA therapies
- Measurable disease by at least one of these: serum M-protein 0.5 g/dL, urine M-protein 200 mg/24 h, involved/uninvolved FLC difference >10 mg/dL, biopsy-proven plasmacytoma, or bone marrow plasma cells >30% of total
- At least 18 years of age
- ECOG performance status of 0 or 1
- Adequate kidney, liver, lung, and heart function as defined by creatinine clearance 50 mL/min/1.73 m2 or equivalent, ALT 5 x ULN, total bilirubin 2.0 x ULN (with exceptions), oxygen saturation >91% on room air, and LVEF 45% confirmed within 28 days
- Agreement to use 2 forms of contraception, including a barrier method, before and for 12 months after treatment if of childbearing potential
- Ability to understand and sign informed consent
You will not qualify if you...
- Systemic therapy for multiple myeloma within 14 days before planned leukapheresis
- History of other cancers except treated non-melanoma skin cancers or cancers treated over 2 years ago with no disease evidence
- Currently receiving other investigational agents
- Receipt of any cellular therapy within 8 weeks before conditioning
- History of allergic reactions to similar compounds as CS1 CAR-T or study agents
- History of Grade 3 cytokine release syndrome or neurotoxicity with CAR-T therapies
- Active hepatitis B or C, uncontrolled infections, or HIV infection
- Active infection or serious medical condition impairing protocol treatment
- Pregnant or breastfeeding women; negative pregnancy test required within 14 days before entry if applicable
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Washington University School of Medicine
St Louis, Missouri, United States, 63110
Actively Recruiting
Research Team
A
Armin Ghobadi, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here